Scribd
Upload
57 views58 pages

Slides DIABETES

The document discusses a novel dual GIP and GLP-1 receptor agonist called tirzepatide. It summarizes clinical trials that evaluated tirzepatide's effects on glycemic control, body weight, and cardiovascular outcomes in patients with type 2 diabetes. Tirzepatide demonstrated greater reductions in HbA1c and body weight compared to other diabetes medications, with a generally well-tolerated safety profile.

Uploaded by

J Ignacio Valverde S (jignaciovs)
Copyright
© © All Rights Reserved
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as PPTX, PDF, TXT or read online on Scribd
57 views58 pages

Slides DIABETES

The document discusses a novel dual GIP and GLP-1 receptor agonist called tirzepatide. It summarizes clinical trials that evaluated tirzepatide's effects on glycemic control, body weight, and cardiovascular outcomes in patients with type 2 diabetes. Tirzepatide demonstrated greater reductions in HbA1c and body weight compared to other diabetes medications, with a generally well-tolerated safety profile.

Uploaded by

J Ignacio Valverde S (jignaciovs)
Copyright
© © All Rights Reserved
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as PPTX, PDF, TXT or read online on Scribd
You are on page 1/ 58

Incretin Concept and Potential Role of GIP

Evolving GLP-1 and GIP Insulinotropic


Concept
Incretin Hormonal Changes Post-Bariatric
Surgery
Dual Peptide Agonists in Clinical
Development
Insulinotropic Effects of GLP-1 and GIP
T2D and Healthy Controls
Insulinotropic Effects of GLP-1 and GIP
T2D and Healthy Controls
Insulinotropic Effects of GIP
T2D and Healthy Controls
GIP Effects on Glucagon Secretion
Areas of Research
Role of GIP and GLP-1
Tirzepatide
A Novel Dual GIP and GLP-1 Receptor
Agonist
Change in Insulin Secretion Rate
Change in Whole-Body Insulin Sensitivity
Mixed Meal Tolerance
Mixed Meal Tolerance -- Glucagon AUC
The SURPASS Program
The SURPASS Clinical Program in T2D
The SURPASS Clinical Program in T2D
The SURPASS Clinical Program in T2D
SURPASS-4
HbA1c and FSG Levels over Time
SURPASS-4 at 52 Weeks
HbA1c Change From Baseline, % Patients
Achieving HbA1c Targets
SURPASS-4 at 52 Weeks
Weight Change From Baseline, % Patients
Weight Loss ≥ 5%
SURPASS-4 at 52 Weeks
Weight Change From Baseline, % Patients
Weight Loss ≥ 15%
SURPASS-4 at 52 Weeks
MACE-4 Kaplan-Meier Plot
How Does Tirzepatide Compare to
Titrated Insulin Therapy?
SURPASS-3
How Does Tirzepatide Compare to Titrated
Insulin Therapy?
SURPASS-3
How Does Tirzepatide Compare to Titrated Insulin Therapy?
SURPASS-3
How Does Tirzepatide Compare to Titrated Insulin Therapy?
SURPASS-3
Impact On Body Weight
SURPASS-3
Impact On Body Weight
SURPASS 2
Incidence of Nausea Over Time
SURPASS Program
Prevalence of Vomiting, Diarrhea, and
Nausea
Tirzepatide and HbA1C Reduction at Early
Diabetes Stage
The SURPASS Program
HbA1c Change From Baseline to Primary Endpoint
The SURPASS Program
Proportion of Patients Achieving HbA1c < 7.0% (53
mmol/mol)*
Tirzepatide and Weight Reduction
The SURPASS Program
Proportion of Patients Achieving ≥ 5% Weight Loss*
The SURPASS Program
Proportion of Patients Achieving ≥ 15% Weight Loss*
The SURPASS Program
Proportion of Patients Achieving ≥ 15% Weight Loss*
GLP-1 Receptor Agonists at Higher Doses
GLP-1 RA Proved Efficacy and Safety at
Higher Doses
Tirzepatide at Higher Doses?
SURPASS 1 and 2
Tirzepatide Dose Escalation Scheme
Tirzepatide 15 mg Maintenance Dose?
Tirzepatide vs Dulaglutide
GLP-1 RAs Same Efficacy on Glycemia?
GLP-1 RAs Have Demonstrated Efficacy in
HbA1c Reduction
Where Does Tirzepatide Fit in the Algorithm
of T2D treatment?
Tirzepatide Positioning in T2D Algorithm
Expert Perspective
Take-Home Messages

You might also like